People · Operator
Named in public records as an officer, director or promoter · active 2010–2011 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Link Medicine Corp | — | Biotechnology | Series B | $64.8M | $190.8M | 2010 |
David Michael Frankel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Michael Frankel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Ross | 1 | 18 |
| David Guyer | 1 | 8 |
| David Neafus | 1 | 7 |
| Nick Galakatos | 1 | 3 |
| John F. Dee | 1 | 2 |
| Adam J. Rosenberg | 1 | 2 |
| Scott Young | 1 | 2 |
| Nick E. Galakatos | 1 | 1 |
| Peter T. Lansbury | 1 | 1 |
| Edward Scolnick | 1 | 1 |
| Michael E. Fitzgerald | 1 | 1 |
| Michael E. Ross | 1 | 1 |
| Michael E. Solomon | 1 | 1 |
| Edward E. Scolnick | 1 | 1 |
| David E. Guyer | 1 | 1 |
| R. Michael Poole | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.